Re: 4.75% Convertible Senior Notes due 2015 (CUSIP No. 45337C AH5) (the “2015 Senior Notes”)

Exhibit 10.3

		Incyte Corporation
		Experimental Station
		Xx. 000 & Xxxxx Xxxx Xxxx
		Xxxxxxxxxx, Xxxxxxxx 00000
	Tel	000.000.0000
	Fax	000.000.0000
	Web	xxx.xxxxxx.xxx

November 8, 2013

The Holders set forth on the

Signature page to this Agreement

Re: 4.75% Convertible Senior Notes due 2015 (CUSIP No. 45337C AH5) (the “2015 Senior Notes”)

Ladies and Gentlemen:

By entering into this letter agreement (this “Agreement”), each party signing this Agreement under the heading “HOLDER” on the signature page hereto (each a “Holder” and, collectively, the “Holders”) and Incyte Corporation, a Delaware corporation (the “Company”) irrevocably agree as follows:

Such Holder shall sell and transfer to the Company, and the Company shall purchase from such Holder, on the Closing Date (as such term is hereinafter defined), the aggregate principal amount of the Company’s 2015 Senior Notes beneficially owned by the Holder and corresponding to such Holder’s name as set forth on Schedule I hereto  (as to each Holder, the “Seller Notes”) in exchange for the aggregate purchase price in cash equal to the aggregate purchase price of $24,995,714.48 (which represents $4,326.01 for the purchase of each $1,000 principal amount and accrued but unpaid interest with respect to the Seller Notes), with such aggregate amount to be payable among each Holder in the amounts set forth on Schedule I hereto (the “Purchase Price”).

On the Closing Date, upon its receipt and against delivery of the Seller Notes (either through physical delivery of the Seller Notes to the Company or receipt by the Company of confirmation from The Depository Trust Company or the Registrar of the Seller Notes, as applicable, of a book-entry transfer of the Seller Notes into the Company’s name), the Company will deliver to the Holder the Purchase Price by wire transfer in accordance with wire instructions provided by the Holders as set forth in Schedule I hereto. Each Holder hereby agrees that the aggregate principal amount and all accrued unpaid interest on the Seller Notes shall be cancelled in connection with the payment of the Purchase Price and that Holder will not be entitled to any other payment or amount with respect to the Seller Notes.

The “Closing Date” shall mean the earlier to occur of (i) the date of closing of the Company’s announced private offering of convertible senior notes due 2018 and convertible senior notes due 2020 or (ii) the 5th business day following the date of this Agreement.

Each Holder hereby represents and warrants to the Company that each Holder is the sole legal and beneficial owner of the Seller Notes, and, upon the Closing, the Company will acquire the Seller Notes free and clear of any liens, encumbrances, pledges, security interests or other restrictions or claims of third parties.

Each of the Company and each Holder agree to promptly execute and deliver such further agreements and instruments and take such further actions, as the other may reasonably request in order to carry out the purposes and intent of this Agreement.

This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed an original, but all of which taken together shall constitute one and the same instrument.

Please confirm your agreement to the foregoing by signing this Agreement in the space provided below and returning a signed copy of this Agreement by telecopy to the attention of Xxxxx X. Xxxxxxxx, telecopy number (302)                  .

(Signature Pages Follow)

	INCYTE CORPORATION
	By:	/s/ Xxxxx X. Xxxxxxxx
		Name: Xxxxx X. Xxxxxxxx
		Title: Executive Vice President and
		Chief Financial Officer

(Signature Page to Debt Repurchase Agreement — Xxxxx Brothers)

	Agreed:
	HOLDERS:
	667, L.P. (account #1),
	BY:  XXXXX BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Xxxxx Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner.
	By:	/s/ Xxxxx Xxxxxxx
	Xxxxx Xxxxxxx
	President
	667, L.P. (account #2),
	BY: XXXXX BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Xxxxx Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner.
	By:	/s/ Xxxxx Xxxxxxx
	Xxxxx Xxxxxxx
	President
	XXXXX BROTHERS LIFE SCIENCES, L.P.
	By: XXXXX BROS. ADVISORS LP, , management company and investment adviser to Xxxxx Brothers Life Sciences, L.P., pursuant to authority granted to it by Xxxxx Brothers Life Sciences Capital, L.P., general partner to Xxxxx Brothers Life Sciences, L.P., and not as the general partner.
	By:	/s/ Xxxxx Xxxxxxx
	Xxxxx Xxxxxxx
	President

(Signature Page to Debt Repurchase Agreement)

	14159, L.P.,
	By: XXXXX BROS. ADVISORS LP, management company and investment adviser to 14159, L.P., pursuant to authority granted to it by 14159 Capital, L.P., general partner to 14159, L.P., and not as the general partner.
	By:	/s/ Xxxxx Xxxxxxx
	Xxxxx Xxxxxxx
	President

(Signature Page to Debt Repurchase Agreement)

Schedule I

HOLDER: 667, L.P.

Aggregate Principal Amount of the 2015 Senior Notes sold to the Company: $1,084,000

Purchase Price: $4,689,400.22

HOLDER: Xxxxx Brothers Life Sciences, L.P.

Aggregate Principal Amount of the 2015 Senior Notes sold to the Company: $4,567,000

Purchase Price: $19,756,910.35

HOLDER: 14159, L.P.

Aggregate Principal Amount of the 2015 Senior Notes sold to the Company: $127,000

Purchase Price: $549,403.90

Wire Instructions:

***